Issues with EpiPens prompt FDA alert By James L. Ferraro | Pharmaceutical Litigation | Last Modified on Feb 20, 2026 Read More
What does mesothelioma actually do to the... By James L. Ferraro | Mesothelioma | Last Modified on Feb 20, 2026 Read More
Ranitidine recalls continue, but don’t get the... By James L. Ferraro | Zantac Recall | Last Modified on Feb 20, 2026 Read More
Cancer isn’t the only concern in Roundup... By James L. Ferraro | Roundup Litigation | Last Modified on Feb 23, 2026 Read More
Did landlord improperly dispose of asbestos during... By James L. Ferraro | Mesothelioma | Last Modified on Feb 23, 2026 Read More
FDA continues to find nitrosamines in popular... By James L. Ferraro | Pharmaceutical Litigation | Last Modified on Feb 27, 2026 Read More
Issues with valsartan continue despite investigations and... By James L. Ferraro | Pharmaceutical Litigation | Last Modified on Feb 20, 2026 Read More
Local cop hired Kelley Ferraro to battle... By James L. Ferraro | Zantac Recall | Last Modified on Feb 27, 2026 Read More
Judge consolidates Zantac claims: What does it... By James L. Ferraro | Zantac Recall | Last Modified on Feb 27, 2026 Read More
Should the Food and Drug Administration recall... By James L. Ferraro | Pharmaceutical Litigation | Last Modified on Feb 27, 2026 Read More
Zantac recall: Was there a breakdown in... By James L. Ferraro | Zantac Recall | Last Modified on Feb 20, 2026 Read More
For your safety, choose the right asbestos... By James L. Ferraro | Asbestos Exposure & Claims | Last Modified on Feb 27, 2026 Read More